- Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy
-
Tate K, Yoshida H, Ishikawa M, Uehara T, Ikeda SI, Hiraoka N, Kato T
- KMID: 2409935
- J Gynecol Oncol.
- 2018 May;29(3):e34.
- doi: 10.3802/jgo.2018.29.e34
OBJECTIVE: Uterine serous carcinoma (USC) is an aggressive type 2 endometrial cancer. Data on prognostic factors for patients with early-stage USC without adjuvant therapy are limited. This study aims to... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma
-
Yoneoka Y, Yoshida H, Ishikawa M, Shimizu H, Uehara T, Murakami T, Kato T
- KMID: 2429576
- J Gynecol Oncol.
- 2019 Jan;30(1):e7.
- doi: 10.3802/jgo.2019.30.e7
OBJECTIVE: Gynecologists occasionally encounter synchronous endometrial and ovarian endometrioid carcinoma (SEO-EC) patients who show favorable prognosis than locally advanced or metastatic disease patients. This study aimed to elucidate prognostic factors... -
- CITED
-
- Close
- SHARE
-
- Close
- Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
-
Yoneoka Y, Ishikawa M, Uehara T, Shimizu H, Uno M, Murakami T, Kato T
- KMID: 2457157
- J Gynecol Oncol.
- 2019 Sep;30(5):e81.
- doi: 10.3802/jgo.2019.30.e81
OBJECTIVE: To treat advanced ovarian cancer, interval debulking surgery (IDS) is performed after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS group). If we expect that complete... -
- CITED
-
- Close
- SHARE
-
- Close
